Bristol Myers dips on ‘confounding’ lung drug results

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 12 Oct, 15:35 UTC

Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, adding to analyst questions about the therapy’s prospects.

science

Sources

• T2Bristol Myers dips on ‘confounding’ lung drug resultsBioPharma Dive / Healthcare Dive / MedTech Dive12 Oct, 15:35